Is Veeva's Vault CRM Emerging as the Standard for Top Biopharma?
VEEV's Vault CRM is gaining traction with top biopharma firms like Merck, Gilead, and BMS, signaling its rise as the industry's commercial standard.
Here's Why IQVIA Holdings ( IQV ) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
This Thomson Reuters Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Charles River ( NYSE:CRL ) , Dick's Sporting Goods ( NYSE:DKS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Jefferies analyst David Windley upgraded Charles River Laboratories International, Inc.
Here's Why IQVIA Holdings ( IQV ) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Is DexCom ( DXCM ) Down 7% Since Last Earnings Report?
DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Veeva Systems Lifts Outlook on CRM Wins
Veeva Systems ( NYSE:VEEV ) reported fiscal second quarter 2026 results on August 27, 2025, delivering $789 million in revenue and raising full-year billings guidance by $35 million. The quarter featured a strategic resolution withIQVIA ( NYSE: IQV ) , rapid Vault CRM adoption among top-20 ...
Firefly Stock Jumps As Nvidia Partnership Boosts AI-Driven EEG Technology For Neurological Care - NVIDIA ( NASDAQ:NVDA ) , Firefly Neuroscience ( NASDAQ:AIFF )
Firefly stock jumped 31% after unveiling CLEAR, an AI-driven EEG platform powered by Nvidia GPUs for faster, cleaner brain data. Nvidia deepened healthcare ties with Novo Nordisk and IQVIA, pushing AI into drug discovery and pharma workflows.
IQVIA ( IQV ) Down 1.1% Since Last Earnings Report: Can It Rebound?
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why IQVIA Holdings ( IQV ) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
UMAC Gears Up to Report Q2 Earnings: What's in the Offing?
Unusual Machines prepares for second-quarter 2025 results, with revenues projected to soar more than 50% y/y on strong U.S. drone market tailwinds.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Avis Budget Stock Declines 22% Since Reporting Q2 Earnings Miss
CAR plunges 22% after second-quarter 2025 earnings and revenues miss estimates despite a nearly 98% YTD surge in shares.
Gartner Earnings Surpass Estimates in Q2, Revenues Increase Y/Y
IT posts strong second-quarter 2025 with EPS up 18.5% and revenues rising 5.6% y/y, but trims its full-year revenue and EBITDA guidance.
Verisk Earnings & Revenues Surpass Estimates in Q2, Increase Y/Y
VRSK posts 8.1% y/y EPS growth in second-quarter 2025, and lifts its revenue and EBITDA guidance despite a lowered EPS outlook.
Vivos Therapeutics Adds to Management Team to Support Expansion and Growth
LITTLETON, Colo., July 30, 2025 ( GLOBE NEWSWIRE ) -- Vivos Therapeutics, Inc. ( NASDAQ: VVOS ) ( "Vivos" or the "Company" ) , a pioneering medical technology company revolutionizing the treatment of obstructive sleep apnea ( OSA ) and snoring, today announced the appointments of Michael ( Mike ...
Vivos Therapeutics Adds to Management Team to Support Expansion and Growth - Vivos Therapeutics ( NASDAQ:VVOS )
LITTLETON, Colo., July 30, 2025 ( GLOBE NEWSWIRE ) -- Vivos Therapeutics, Inc. VVOS ( "Vivos" or the "Company" ) , a pioneering medical technology company revolutionizing the treatment of obstructive sleep apnea ( OSA ) and snoring, today announced the appointments of Michael ( Mike ) E.
WM Earnings & Revenues Beat Estimates in Q2, Increase Y/Y
WM reports 19% y/y revenue growth and a 5.5% EPS rise in second-quarter 2025 despite lowering the yearly revenue guidance.
Fiserv Q2 Earnings Beat Estimates on Strong Margins, Revenues Miss
FI tops second-quarter 2024 earnings estimates on strong margins and segment growth. However, its shares drop 15.7% on the revenue miss.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
IQVIA ( IQV ) Reliance on International Sales: What Investors Need to Know
Explore IQVIA's (IQV) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Thermo Fisher, Baker Hughes And IQVIA Holdings Are Among Top 10 Large Cap Gainers Last Week ( July 21-July 25 ) : Are The Others In Your Portfolio? - Astera Labs ( NASDAQ:ALAB ) , Baker Hughes ( NASDAQ:BKR )
Medpace surged over 137% after crushing Q2 earnings estimates. Strong earnings and raised guidance drove sharp gains in pharma and tech names. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily. These ten large-cap stocks were top performers last week.
Veeva's Vault Vision: Can It Thrive After Parting With Salesforce?
VEEV stock climbs 36% YTD as it accelerates its shift off Salesforce, betting on Vault to power future growth in life sciences.
Fiserv's Q2 Earnings Surpass Estimates, Revenues Increase Y/Y
FI posts solid second-quarter 2025 earnings growth, which has boosted full-year EPS outlook, but revenue miss keeps the stock trailing its peers.
Stock Market News for Jul 23, 2025
Wall Street closed mixed on Tuesday as market participants were busy weighing uncertainties related to tariff rates and trade policies.
IQVIA Earnings & Revenues Beat Estimates in Q2, Rise Y/Y
IQV tops second-quarter 2025 estimates, with earnings up 6.4% and revenue rising 5.5%. It cuts the 2025 EBITDA guidance.
IQVIA Holdings ( IQV ) Q2 Earnings and Revenues Surpass Estimates
IQVIA (IQV) delivered earnings and revenue surprises of +1.81% and +1.48%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Countdown to IQVIA ( IQV ) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Get a deeper insight into the potential performance of IQVIA (IQV) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Analysts Estimate Thermo Fisher Scientific ( TMO ) to Report a Decline in Earnings: What to Look Out for
Thermo Fisher (TMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IQVIA Gears Up to Report Q2 Earnings: What's in Store for the Stock?
IQV is set to report Q2 results on July 22, with both earnings and revenues expected to rise on strong demand across segments.
IQVIA Holdings ( IQV ) Earnings Expected to Grow: Should You Buy?
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why IQVIA Holdings ( IQV ) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Veeva Expands Market Reach Through Targeted Strategic Partnerships
VEEV gains momentum in 2025 with strategic partnerships fueling growth in AI, clinical research, and compliance.
VEEV Rises 29% in 3 Months: Should You Buy the Stock Now or Wait?
Veeva Systems gains momentum as strong earnings, Vault CRM growth, and new AI tools reinforce its life sciences edge.
VEEV Integrates GenAI in Vault Platform to Drive Workflow Automation
Veeva's new AI layer in Vault boosts automation and deepens pharma reliance, sharpening its edge in life sciences tech.
Is IQVIA Hldgs Gaining or Losing Market Support? - IQVIA Hldgs ( NYSE:IQV )
IQVIA Hldgs's IQV short percent of float has risen 29.88% since its last report. The company recently reported that it has 9.33 million shares sold short, which is 6.26% of all regular shares that are available for trading.
Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
TEM is scaling fast. Data and Services revenues soar 43%, fueled by big-name pharma and AI model deals.
Nvidia Just Partnered With A Weight-Loss Giant, But It's Not About Pills - NVIDIA ( NASDAQ:NVDA ) , Novo Nordisk ( NYSE:NVO ) , IQVIA Hldgs ( NYSE:IQV )
Novo Nordisk will use Nvidia BioNeMo, NeMo microservices, and Omniverse for AI drug discovery. IQVIA's AI agents will analyze treatment data in days instead of weeks for faster development. 3 Summer 'Power Patterns' Are About to Trigger ( One With 90% Win Rate ) - Get The Details Now
IQVIA Stock: Stuck In A Time Spiral - Value Play Or Bull Trap? - IQVIA Hldgs ( NYSE:IQV )
IQVIA ( IQV ) is currently in Phase 18 of its 18-Phase Adhishthana Cycle. On the surface, the stock might appear poised for a new move, but when analyzed through a multi-timeframe lens using the Adhishthana Principles, the picture is more complex.
Doximity Declines 4.4% in a Month: How to Play the Stock Now?
DOCS slips 4.4% in a month despite strong Q4 results, margin gains and raised guidance -- is there a buying opportunity?
P/E Ratio Insights for IQVIA Hldgs - IQVIA Hldgs ( NYSE:IQV )
In the current market session, IQVIA Hldgs Inc. IQV price is at $139.70, after a 1.20% increase. However, over the past month, the stock fell by 10.72%, and in the past year, by 39.57%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing ...
Investing in IQVIA ( IQV ) ? Don't Miss Assessing Its International Revenue Trends
Evaluate IQVIA's (IQV) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
IQVIA Earnings & Revenues Beat Estimates in Q1, Increase Y/Y
IQV's top line in the first quarter of 2025 benefits from the Research and Development, and Technology and Analytics segments.
IQVIA Beats Q1 Earnings Expectations Despite Sector Uncertainty, Company Navigating Market Conditions 'Effectively' Says CEO - IQVIA Hldgs ( NYSE:IQV )
Q1 adjusted EPS: $2.70 vs. $2.63 expected; revenue: $3.83 billion vs. $3.77 billion consensus. 2025 sales outlook raised to $16-$16.4 billion; EPS guidance reaffirmed at $11.70-$12.10. Feel unsure about the market's next move?
IQVIA Holdings ( IQV ) Surpasses Q1 Earnings and Revenue Estimates
IQVIA (IQV) delivered earnings and revenue surprises of 2.66% and 1.55%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
IQVIA Gears Up to Report Q1 Earnings: What's in Store for the Stock?
Growth across the R&DS and TAS segments is anticipated to have boosted IQV's top line in the first quarter of 2025.
IQVIA ( IQV ) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Evaluate the expected performance of IQVIA (IQV) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
RxSight, Inc. ( RXST ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
RxSight (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IQVIA Holdings ( IQV ) Earnings Expected to Grow: Should You Buy?
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IQVIA ( IQV ) Moves 8.7% Higher: Will This Strength Last?
IQVIA (IQV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
